Update
$Lumos Pharma(LUMO.US$ © Reuters. Lumos Pharma (ticker: NASDAQ:LUMO) has announced promising top-line results from its OraGrowtH210 and OraGrowtH212 trials for LUM-201, highlighting its potential as an oral treatment for pediatric growth hormone deficiency (PGHD). The company detailed plans for future trials and regulatory discussions during its recent earnings call. With $36.1 million in cash at the end of 2023, Lumos Pharma is funded through Q3 2024 and is actively exploring partnerships and additional indications for LUM-201. Key Takeaways LUM-201 demonstrated efficacy as an oral alternative to injectable treatments for PGHD. The 1.6 mg/kg dose achieved annualized height velocities of 8.2 cm/year at six months and 8 cm/year at 12 months. Comprehensive 12-month data will be presented in Q2 2024, with a Phase III trial initiation planned for Q4 2024. An end-of-Phase II meeting with the FDA is scheduled for Q2 2024 to discuss the Phase III protocol. The company is considering partnerships in ex-US markets and additional indications for LUM-201, including Turner syndrome and non-alcoholic fatty liver disease. Interest from key opinion leaders and patients in the oral form of the drug has been expressed. Lumos Pharma aims to complete enrollment for the global Phase III trial within 15 to 18 months, benefiting from the absence of COVID and limited competition.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
